ReP USP - Resultado da busca

Trabalho de evento-resumo periodico
Molecular mechanisms associated with autophagy inhibition to overcome resistance to FLT3 inhibitors (2024)
Melo, Manuela Albuquerque de ; Pereira-Martins, Diego Antonio ; Macedo, Brunno Gilberto Santos ; Miranda, Lívia Bassani Lins De ; Scheucher, Priscila Santos ; Weinhäuser, Isabel ; Huls, Gerwin A. ; Schuringa, Jan Jacob ; Traina, Fabiola ; Machado Neto, João Agostinho
Source: Blood. Conference titles: The 66th ASH Annual Meeting. Unidades: FMRP, ICB
Subjects: FARMACOLOGIA, LEUCEMIA MIELOIDE AGUDA, ANTIMALÁRICOS, MITOCÔNDRIAS, PROTEÔMICA, CAMUNDONGOS, LINHAGEM CELULAR, SOBREVIVÊNCIA CELULAR, ESTUDOS DE COORTES, PROLIFERAÇÃO CELULAR
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MELO, Manuela Albuquerque de et al. Molecular mechanisms associated with autophagy inhibition to overcome resistance to FLT3 inhibitors. Blood. Washington, DC: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1182/blood-2024-203390. Acesso em: 24 nov. 2025. , 2024
APA
Melo, M. A. de, Pereira-Martins, D. A., Macedo, B. G. S., Miranda, L. B. L. D., Scheucher, P. S., Weinhäuser, I., et al. (2024). Molecular mechanisms associated with autophagy inhibition to overcome resistance to FLT3 inhibitors. Blood. Washington, DC: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. doi:10.1182/blood-2024-203390
NLM
Melo MA de, Pereira-Martins DA, Macedo BGS, Miranda LBLD, Scheucher PS, Weinhäuser I, Huls GA, Schuringa JJ, Traina F, Machado Neto JA. Molecular mechanisms associated with autophagy inhibition to overcome resistance to FLT3 inhibitors [Internet]. Blood. 2024 ; 144( supl. 1): 2752-2753.[citado 2025 nov. 24 ] Available from: https://doi.org/10.1182/blood-2024-203390
Vancouver
Melo MA de, Pereira-Martins DA, Macedo BGS, Miranda LBLD, Scheucher PS, Weinhäuser I, Huls GA, Schuringa JJ, Traina F, Machado Neto JA. Molecular mechanisms associated with autophagy inhibition to overcome resistance to FLT3 inhibitors [Internet]. Blood. 2024 ; 144( supl. 1): 2752-2753.[citado 2025 nov. 24 ] Available from: https://doi.org/10.1182/blood-2024-203390
Artigo de periodico
Autophagy induction constitutes a targetable vulnerability in FLT3-mutant acute Myeloid Leukemia cells treated with FLT3-inhibitors (2023)
Melo, Manuela Albuquerque de ; Macedo, Brunno Gilberto Santos ; Fonseca, Natasha Peixoto ; Scheucher, Priscila Santos ; Martins, Diego Antonio Pereira ; Traina, Fabiola ; Machado Neto, João Agostinho
Source: Blood. Conference titles: 65th ASH Annual Meeting Abstracts. Unidades: FMRP, ICB
Subjects: FARMACOLOGIA, HEMATOLOGIA, CÉLULAS MIELOIDES, LEUCEMIA MIELOIDE AGUDA, NEOPLASIAS POR TIPO HISTOLÓGICO, ANTINEOPLÁSICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MELO, Manuela Albuquerque de et al. Autophagy induction constitutes a targetable vulnerability in FLT3-mutant acute Myeloid Leukemia cells treated with FLT3-inhibitors. Blood, v. 142, n. Supl. 1, p. 5752, 2023Tradução . . Disponível em: https://doi.org/10.1182/blood-2023-190724. Acesso em: 24 nov. 2025.
APA
Melo, M. A. de, Macedo, B. G. S., Fonseca, N. P., Scheucher, P. S., Martins, D. A. P., Traina, F., & Machado Neto, J. A. (2023). Autophagy induction constitutes a targetable vulnerability in FLT3-mutant acute Myeloid Leukemia cells treated with FLT3-inhibitors. Blood, 142( Supl. 1), 5752. doi:10.1182/blood-2023-190724
NLM
Melo MA de, Macedo BGS, Fonseca NP, Scheucher PS, Martins DAP, Traina F, Machado Neto JA. Autophagy induction constitutes a targetable vulnerability in FLT3-mutant acute Myeloid Leukemia cells treated with FLT3-inhibitors [Internet]. Blood. 2023 ; 142( Supl. 1): 5752.[citado 2025 nov. 24 ] Available from: https://doi.org/10.1182/blood-2023-190724
Vancouver
Melo MA de, Macedo BGS, Fonseca NP, Scheucher PS, Martins DAP, Traina F, Machado Neto JA. Autophagy induction constitutes a targetable vulnerability in FLT3-mutant acute Myeloid Leukemia cells treated with FLT3-inhibitors [Internet]. Blood. 2023 ; 142( Supl. 1): 5752.[citado 2025 nov. 24 ] Available from: https://doi.org/10.1182/blood-2023-190724
Trabalho de evento-resumo periodico
Frequência e ativação de células citotóxicas antitumorais são biomarcadores de resposta e remissão livre de tratamento na leucemia mieloide crônica (2023)
Binelli, Larissa Sarri; Palma, Leonardo Carvalho ; Garcia, Camila Araújo Bernardino ; Marani, Leticia Olops ; Medeiros, Mariana ; Lopes, Izabela Aparecida; Scheucher, Priscila Santos ; Schiavinato, Josiane Lilian dos Santos ; Traina, Fabiola ; Garibaldi, P. M. M.; Castro, Fabíola Attié de ; Bassan, Vitor Leonardo ; Duarte, G. O.; Pagnano, K. B. B.; Figueiredo-pontes, Lorena Lobo
Source: Hematology, Transfusion and Cell Therapy. Conference titles: Congresso Brasileiro de Hematologia, Hemoterapia e Terapia Celular - HEMO. Unidades: FMRP, FCFRP
Subjects: LEUCEMIA MIELOIDE, REGRESSÃO NEOPLÁSICA ESPONTÂNEA, LINFÓCITOS T, BIOMARCADORES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BINELLI, Larissa Sarri et al. Frequência e ativação de células citotóxicas antitumorais são biomarcadores de resposta e remissão livre de tratamento na leucemia mieloide crônica. Hematology, Transfusion and Cell Therapy. São José do Rio Preto: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1016/j.htct.2023.09.425. Acesso em: 24 nov. 2025. , 2023
APA
Binelli, L. S., Palma, L. C., Garcia, C. A. B., Marani, L. O., Medeiros, M., Lopes, I. A., et al. (2023). Frequência e ativação de células citotóxicas antitumorais são biomarcadores de resposta e remissão livre de tratamento na leucemia mieloide crônica. Hematology, Transfusion and Cell Therapy. São José do Rio Preto: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. doi:10.1016/j.htct.2023.09.425
NLM
Binelli LS, Palma LC, Garcia CAB, Marani LO, Medeiros M, Lopes IA, Scheucher PS, Schiavinato JL dos S, Traina F, Garibaldi PMM, Castro FA de, Bassan VL, Duarte GO, Pagnano KBB, Figueiredo-pontes LL. Frequência e ativação de células citotóxicas antitumorais são biomarcadores de resposta e remissão livre de tratamento na leucemia mieloide crônica [Internet]. Hematology, Transfusion and Cell Therapy. 2023 ; 45 S200-S201.[citado 2025 nov. 24 ] Available from: https://doi.org/10.1016/j.htct.2023.09.425
Vancouver
Binelli LS, Palma LC, Garcia CAB, Marani LO, Medeiros M, Lopes IA, Scheucher PS, Schiavinato JL dos S, Traina F, Garibaldi PMM, Castro FA de, Bassan VL, Duarte GO, Pagnano KBB, Figueiredo-pontes LL. Frequência e ativação de células citotóxicas antitumorais são biomarcadores de resposta e remissão livre de tratamento na leucemia mieloide crônica [Internet]. Hematology, Transfusion and Cell Therapy. 2023 ; 45 S200-S201.[citado 2025 nov. 24 ] Available from: https://doi.org/10.1016/j.htct.2023.09.425
Artigo de periodico
Altered distribution and function of NK-cell subsets lead to impaired tumor surveillance in JAK2V617F myeloproliferative neoplasms (2022)
Costa, Amanda Fernandes de Oliveira ; Marani, Leticia Olops ; Bianco, Thiago Mantello ; Arantes, Adriana Queiroz; Lopes, Izabela Aparecida; Martins, Diego Antonio Pereira; Palma, Leonardo Carvalho ; Scheucher, Priscila Santos ; Schiavinato, Josiane Lilian dos Santos ; Silva, Cleide Lucia Araújo ; Kobayashi, Susumu S. ; Machado Neto, João Agostinho ; Rego, Eduardo Magalhães ; Welner, Robert Samuel; Pontes, Lorena Lobo de Figueiredo
Source: Frontiers in Immunology. Unidades: FMRP, ICB, FM
Subjects: FARMACOLOGIA, MUTAÇÃO, CITOMETRIA DE FLUXO, CÉLULAS CULTIVADAS DE TUMOR, CÉLULAS DA MEDULA ÓSSEA, LEUCEMIA, CÉLULAS SANGUÍNEAS, MEDULA ÓSSEA, CÉLULAS-TRONCO, LINFÓCITOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
COSTA, Amanda Fernandes de Oliveira et al. Altered distribution and function of NK-cell subsets lead to impaired tumor surveillance in JAK2V617F myeloproliferative neoplasms. Frontiers in Immunology, v. 13, p. 1-15, 2022Tradução . . Disponível em: https://doi.org/10.3389/fimmu.2022.768592. Acesso em: 24 nov. 2025.
APA
Costa, A. F. de O., Marani, L. O., Bianco, T. M., Arantes, A. Q., Lopes, I. A., Martins, D. A. P., et al. (2022). Altered distribution and function of NK-cell subsets lead to impaired tumor surveillance in JAK2V617F myeloproliferative neoplasms. Frontiers in Immunology, 13, 1-15. doi:10.3389/fimmu.2022.768592
NLM
Costa AF de O, Marani LO, Bianco TM, Arantes AQ, Lopes IA, Martins DAP, Palma LC, Scheucher PS, Schiavinato JL dos S, Silva CLA, Kobayashi SS, Machado Neto JA, Rego EM, Welner RS, Pontes LL de F. Altered distribution and function of NK-cell subsets lead to impaired tumor surveillance in JAK2V617F myeloproliferative neoplasms [Internet]. Frontiers in Immunology. 2022 ; 13 1-15.[citado 2025 nov. 24 ] Available from: https://doi.org/10.3389/fimmu.2022.768592
Vancouver
Costa AF de O, Marani LO, Bianco TM, Arantes AQ, Lopes IA, Martins DAP, Palma LC, Scheucher PS, Schiavinato JL dos S, Silva CLA, Kobayashi SS, Machado Neto JA, Rego EM, Welner RS, Pontes LL de F. Altered distribution and function of NK-cell subsets lead to impaired tumor surveillance in JAK2V617F myeloproliferative neoplasms [Internet]. Frontiers in Immunology. 2022 ; 13 1-15.[citado 2025 nov. 24 ] Available from: https://doi.org/10.3389/fimmu.2022.768592
Artigo de periodico
Association between leukocyte telomere length and sex by quantile regression analysis (2022)
Gutierrez-Rodrigues, Fernanda; Alves-Paiva, Raquel M.; Scatena, Natália F.; Martinez, Edson Zangiacomi ; Scheucher, Priscila Santos ; Calado, Rodrigo Tocantins
Source: Hematology, Transfusion and Cell Therapy. Unidade: FMRP
Subjects: TELÔMERO, REGRESSÃO LINEAR, ENVELHECIMENTO, SEXO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GUTIERREZ-RODRIGUES, Fernanda et al. Association between leukocyte telomere length and sex by quantile regression analysis. Hematology, Transfusion and Cell Therapy, v. 44, n. 3, p. 346-351, 2022Tradução . . Disponível em: https://doi.org/10.1016/j.htct.2020.12.005. Acesso em: 24 nov. 2025.
APA
Gutierrez-Rodrigues, F., Alves-Paiva, R. M., Scatena, N. F., Martinez, E. Z., Scheucher, P. S., & Calado, R. T. (2022). Association between leukocyte telomere length and sex by quantile regression analysis. Hematology, Transfusion and Cell Therapy, 44( 3), 346-351. doi:10.1016/j.htct.2020.12.005
NLM
Gutierrez-Rodrigues F, Alves-Paiva RM, Scatena NF, Martinez EZ, Scheucher PS, Calado RT. Association between leukocyte telomere length and sex by quantile regression analysis [Internet]. Hematology, Transfusion and Cell Therapy. 2022 ; 44( 3): 346-351.[citado 2025 nov. 24 ] Available from: https://doi.org/10.1016/j.htct.2020.12.005
Vancouver
Gutierrez-Rodrigues F, Alves-Paiva RM, Scatena NF, Martinez EZ, Scheucher PS, Calado RT. Association between leukocyte telomere length and sex by quantile regression analysis [Internet]. Hematology, Transfusion and Cell Therapy. 2022 ; 44( 3): 346-351.[citado 2025 nov. 24 ] Available from: https://doi.org/10.1016/j.htct.2020.12.005
Trabalho de evento-resumo periodico
Dysregulated activating and inhibitory receptors on natural killer cells predicts immune escape and poor outcomes in acute myeloid leukemia (2022)
Costa, Amanda Fernandes de Oliveira ; Kuznetsova, Valeriya; Marani, Leticia Olops ; Lopes, Izabela Aparecida; Binelli, Larissa S; Scheucher, Priscila Santos ; Schiavinato, Josiane Lilian dos Santos ; Faria, Joana Teresa Bisinella de ; Madeira, Maria Isabel A; Pagnano, Katia B; Duarte, Bruno K; Gloria, Ana Beatriz F; Rego, Eduardo Magalhães ; Traina, Fabiola ; Welner, Robert; Figueiredo-Pontes, Lorena Lobo
Source: Blood. Conference titles: ASH Annual Meeting. Unidades: FMRP, FM
Subjects: LEUCEMIA MIELOIDE AGUDA, FISIOPATOLOGIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
COSTA, Amanda Fernandes de Oliveira et al. Dysregulated activating and inhibitory receptors on natural killer cells predicts immune escape and poor outcomes in acute myeloid leukemia. Blood. Washington: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1182/blood-2022-168178. Acesso em: 24 nov. 2025. , 2022
APA
Costa, A. F. de O., Kuznetsova, V., Marani, L. O., Lopes, I. A., Binelli, L. S., Scheucher, P. S., et al. (2022). Dysregulated activating and inhibitory receptors on natural killer cells predicts immune escape and poor outcomes in acute myeloid leukemia. Blood. Washington: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. doi:10.1182/blood-2022-168178
NLM
Costa AF de O, Kuznetsova V, Marani LO, Lopes IA, Binelli LS, Scheucher PS, Schiavinato JL dos S, Faria JTB de, Madeira MIA, Pagnano KB, Duarte BK, Gloria ABF, Rego EM, Traina F, Welner R, Figueiredo-Pontes LL. Dysregulated activating and inhibitory receptors on natural killer cells predicts immune escape and poor outcomes in acute myeloid leukemia [Internet]. Blood. 2022 ; 140 9113-9114.[citado 2025 nov. 24 ] Available from: https://doi.org/10.1182/blood-2022-168178
Vancouver
Costa AF de O, Kuznetsova V, Marani LO, Lopes IA, Binelli LS, Scheucher PS, Schiavinato JL dos S, Faria JTB de, Madeira MIA, Pagnano KB, Duarte BK, Gloria ABF, Rego EM, Traina F, Welner R, Figueiredo-Pontes LL. Dysregulated activating and inhibitory receptors on natural killer cells predicts immune escape and poor outcomes in acute myeloid leukemia [Internet]. Blood. 2022 ; 140 9113-9114.[citado 2025 nov. 24 ] Available from: https://doi.org/10.1182/blood-2022-168178
Artigo de periodico
Differential cytotoxic activity of pharmacological inhibitors of IGF1R-related pathways in JAK2(V617F) driven cells (2022)
Fernandes, Jaqueline Cristina; Fenerich, Bruna Alves ; Alves-silva, Antonio Bruno; Fonseca, Natasha Peixoto ; Coelho-silva, Juan Luiz ; Scheucher, Priscila Santos ; Rego, Eduardo Magalhães ; Figueiredo-pontes, Lorena Lobo ; Machado Neto, João Agostinho ; Traina, Fabiola
Source: Toxicology in vitro. Unidades: FMRP, FM, ICB
Subjects: RECEPTORES HORMONAIS, HORMÔNIO DO CRESCIMENTO, ANTINEOPLÁSICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FERNANDES, Jaqueline Cristina et al. Differential cytotoxic activity of pharmacological inhibitors of IGF1R-related pathways in JAK2(V617F) driven cells. Toxicology in vitro, v. 83, 2022Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/50423. Acesso em: 24 nov. 2025.
APA
Fernandes, J. C., Fenerich, B. A., Alves-silva, A. B., Fonseca, N. P., Coelho-silva, J. L., Scheucher, P. S., et al. (2022). Differential cytotoxic activity of pharmacological inhibitors of IGF1R-related pathways in JAK2(V617F) driven cells. Toxicology in vitro, 83. doi:10.1016/j.tiv.2022.105384
NLM
Fernandes JC, Fenerich BA, Alves-silva AB, Fonseca NP, Coelho-silva JL, Scheucher PS, Rego EM, Figueiredo-pontes LL, Machado Neto JA, Traina F. Differential cytotoxic activity of pharmacological inhibitors of IGF1R-related pathways in JAK2(V617F) driven cells [Internet]. Toxicology in vitro. 2022 ; 83[citado 2025 nov. 24 ] Available from: https://observatorio.fm.usp.br/handle/OPI/50423
Vancouver
Fernandes JC, Fenerich BA, Alves-silva AB, Fonseca NP, Coelho-silva JL, Scheucher PS, Rego EM, Figueiredo-pontes LL, Machado Neto JA, Traina F. Differential cytotoxic activity of pharmacological inhibitors of IGF1R-related pathways in JAK2(V617F) driven cells [Internet]. Toxicology in vitro. 2022 ; 83[citado 2025 nov. 24 ] Available from: https://observatorio.fm.usp.br/handle/OPI/50423
Artigo de periodico
Phenformin increases early hematopoietic progenitors in the Jak2V617F murine model (2022)
Silva, Antônio Bruno Alves; Fenerich, Bruna Alves ; Fonseca, Natasha Peixoto ; Fernandes, Jaqueline Cristina; Silva, Juan Luiz Coelho da ; Martins, Diego Antonio Pereira ; Bianco, Thiago Mantello ; Scheucher, Priscila Santos ; Rego, Eduardo Magalhães ; Chahud, Fernando ; Machado Neto, João Agostinho ; Pontes, Lorena Lôbo de Figueiredo ; Traina, Fabiola
Source: Investigational New Drugs. Unidades: FMRP, FM, ICB
Subjects: FARMACOLOGIA, CÉLULAS CULTIVADAS DE TUMOR, ANTIDIABÉTICOS (HIPOGLICEMIANTES), HEMATOPOESE, CÉLULAS SANGUÍNEAS, CÉLULAS-TRONCO, DOENÇAS HEMATOLÓGICAS, POLICITEMIA, PLAQUETAS SANGUÍNEAS, ANTINEOPLÁSICOS, CAMUNDONGOS, MODELOS ANIMAIS DE DOENÇAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SILVA, Antônio Bruno Alves et al. Phenformin increases early hematopoietic progenitors in the Jak2V617F murine model. Investigational New Drugs, p. 1-10, 2022Tradução . . Disponível em: https://doi.org/10.1007/s10637-022-01212-y. Acesso em: 24 nov. 2025.
APA
Silva, A. B. A., Fenerich, B. A., Fonseca, N. P., Fernandes, J. C., Silva, J. L. C. da, Martins, D. A. P., et al. (2022). Phenformin increases early hematopoietic progenitors in the Jak2V617F murine model. Investigational New Drugs, 1-10. doi:10.1007/s10637-022-01212-y
NLM
Silva ABA, Fenerich BA, Fonseca NP, Fernandes JC, Silva JLC da, Martins DAP, Bianco TM, Scheucher PS, Rego EM, Chahud F, Machado Neto JA, Pontes LL de F, Traina F. Phenformin increases early hematopoietic progenitors in the Jak2V617F murine model [Internet]. Investigational New Drugs. 2022 ; 1-10.[citado 2025 nov. 24 ] Available from: https://doi.org/10.1007/s10637-022-01212-y
Vancouver
Silva ABA, Fenerich BA, Fonseca NP, Fernandes JC, Silva JLC da, Martins DAP, Bianco TM, Scheucher PS, Rego EM, Chahud F, Machado Neto JA, Pontes LL de F, Traina F. Phenformin increases early hematopoietic progenitors in the Jak2V617F murine model [Internet]. Investigational New Drugs. 2022 ; 1-10.[citado 2025 nov. 24 ] Available from: https://doi.org/10.1007/s10637-022-01212-y
Artigo de periodico
The combination of gefitinib with ATRA and ATO induces myeloid differentiation in acute promyelocytic leukemia resistant cells (2021)
Almeida, Luciana Yamamoto de; Martins, Diego A. Pereira; Weinhäuser, Isabel; Ortiz, César; Cândido, Larissa A.; Lange, Ana Paula; Abreu, Nayara F. de; Mendonza, Sílvia E. S.; Wagatsuma, Virgínia M. de Deus; Nascimento, Mariane C. do; Paiva, Helder H.; Alves-Paiva, Raquel M.; Bonaldo, Camila C. O. M.; Nascimento, Daniele C.; Alves-Filho, José Carlos; Scheucher, Priscila S.; Lima, Ana Silvia Gouvêa de; Schuringa, Jan Jacob; Ammantuna, Emanuele; Ottone, Tiziana; Noguera, Nelida I.; Araujo, Cleide L.; Rego, Eduardo M.
Source: Frontiers in Oncology. Unidades: FMRP, FM
Subjects: LEUCEMIA, CÉLULAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ALMEIDA, Luciana Yamamoto de et al. The combination of gefitinib with ATRA and ATO induces myeloid differentiation in acute promyelocytic leukemia resistant cells. Frontiers in Oncology, v. 11, 2021Tradução . . Disponível em: https://doi.org/10.3389/fonc.2021.686445. Acesso em: 24 nov. 2025.
APA
Almeida, L. Y. de, Martins, D. A. P., Weinhäuser, I., Ortiz, C., Cândido, L. A., Lange, A. P., et al. (2021). The combination of gefitinib with ATRA and ATO induces myeloid differentiation in acute promyelocytic leukemia resistant cells. Frontiers in Oncology, 11. doi:10.3389/fonc.2021.686445
NLM
Almeida LY de, Martins DAP, Weinhäuser I, Ortiz C, Cândido LA, Lange AP, Abreu NF de, Mendonza SES, Wagatsuma VM de D, Nascimento MC do, Paiva HH, Alves-Paiva RM, Bonaldo CCOM, Nascimento DC, Alves-Filho JC, Scheucher PS, Lima ASG de, Schuringa JJ, Ammantuna E, Ottone T, Noguera NI, Araujo CL, Rego EM. The combination of gefitinib with ATRA and ATO induces myeloid differentiation in acute promyelocytic leukemia resistant cells [Internet]. Frontiers in Oncology. 2021 ; 11[citado 2025 nov. 24 ] Available from: https://doi.org/10.3389/fonc.2021.686445
Vancouver
Almeida LY de, Martins DAP, Weinhäuser I, Ortiz C, Cândido LA, Lange AP, Abreu NF de, Mendonza SES, Wagatsuma VM de D, Nascimento MC do, Paiva HH, Alves-Paiva RM, Bonaldo CCOM, Nascimento DC, Alves-Filho JC, Scheucher PS, Lima ASG de, Schuringa JJ, Ammantuna E, Ottone T, Noguera NI, Araujo CL, Rego EM. The combination of gefitinib with ATRA and ATO induces myeloid differentiation in acute promyelocytic leukemia resistant cells [Internet]. Frontiers in Oncology. 2021 ; 11[citado 2025 nov. 24 ] Available from: https://doi.org/10.3389/fonc.2021.686445
Artigo de periodico
STMN1 is highly expressed and contributes to clonogenicity in acute promyelocytic leukemia cells (2021)
Vicari, Hugo Passos ; Silva, Juan Luiz Coelho da ; Martins, Diego Antonio Pereira ; Araujo, Antônio Roberto Lucena de ; Lima, Keli ; Silva, Jean Carlos Lipreri da ; Scheucher, Priscila Santos ; Koury, Luisa C.; Melo, Raul A. de ; Bittencourt, Rosane; Pagnano, Katia ; Nunes, Elenaide ; Fagundes, Evandro Maranhão ; Kerbauy, Fabio; Pontes, Lorena Lobo de Figueiredo ; Costa-Lotufo, Letícia Veras ; Rego, Eduardo Magalhães ; Traina, Fabiola ; Machado Neto, João Agostinho
Source: Investigational New Drugs. Unidades: FMRP, ICB, FM
Subjects: FARMACOLOGIA, CÉLULAS SANGUÍNEAS, CLONAGEM, LEUCEMIA MIELOIDE AGUDA, ONCOPROTEÍNAS, CÉLULAS MIELOIDES, CICLO CELULAR, HEMATOPOESE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
VICARI, Hugo Passos et al. STMN1 is highly expressed and contributes to clonogenicity in acute promyelocytic leukemia cells. Investigational New Drugs, p. 1-15, 2021Tradução . . Disponível em: https://doi.org/10.1007/s10637-021-01197-0. Acesso em: 24 nov. 2025.
APA
Vicari, H. P., Silva, J. L. C. da, Martins, D. A. P., Araujo, A. R. L. de, Lima, K., Silva, J. C. L. da, et al. (2021). STMN1 is highly expressed and contributes to clonogenicity in acute promyelocytic leukemia cells. Investigational New Drugs, 1-15. doi:10.1007/s10637-021-01197-0
NLM
Vicari HP, Silva JLC da, Martins DAP, Araujo ARL de, Lima K, Silva JCL da, Scheucher PS, Koury LC, Melo RA de, Bittencourt R, Pagnano K, Nunes E, Fagundes EM, Kerbauy F, Pontes LL de F, Costa-Lotufo LV, Rego EM, Traina F, Machado Neto JA. STMN1 is highly expressed and contributes to clonogenicity in acute promyelocytic leukemia cells [Internet]. Investigational New Drugs. 2021 ; 1-15.[citado 2025 nov. 24 ] Available from: https://doi.org/10.1007/s10637-021-01197-0
Vancouver
Vicari HP, Silva JLC da, Martins DAP, Araujo ARL de, Lima K, Silva JCL da, Scheucher PS, Koury LC, Melo RA de, Bittencourt R, Pagnano K, Nunes E, Fagundes EM, Kerbauy F, Pontes LL de F, Costa-Lotufo LV, Rego EM, Traina F, Machado Neto JA. STMN1 is highly expressed and contributes to clonogenicity in acute promyelocytic leukemia cells [Internet]. Investigational New Drugs. 2021 ; 1-15.[citado 2025 nov. 24 ] Available from: https://doi.org/10.1007/s10637-021-01197-0
Artigo de periodico
Eltrombopag preferentially expands haematopoietic multipotent progenitors in human aplastic anaemia (2021)
Oliveira, Bruno Quintino de; Catto, Luiz Fernando Bazzo ; Santana, Bárbara Amélia Aparecida; Tellechea, Maria Florencia ; Scheucher, Priscila Santos ; Scheinberg, Phillip; Calado, Rodrigo Tocantins
Source: British Journal of Haematology. Unidade: FMRP
Subjects: ANEMIA, MEDULA ÓSSEA, CÉLULAS SANGUÍNEAS, CÉLULAS-TRONCO, DOENÇAS HEMATOLÓGICAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
OLIVEIRA, Bruno Quintino de et al. Eltrombopag preferentially expands haematopoietic multipotent progenitors in human aplastic anaemia. British Journal of Haematology, v. 193, n. 2, p. 410-414, 2021Tradução . . Disponível em: https://doi.org/10.1111/bjh.17140. Acesso em: 24 nov. 2025.
APA
Oliveira, B. Q. de, Catto, L. F. B., Santana, B. A. A., Tellechea, M. F., Scheucher, P. S., Scheinberg, P., & Calado, R. T. (2021). Eltrombopag preferentially expands haematopoietic multipotent progenitors in human aplastic anaemia. British Journal of Haematology, 193( 2), 410-414. doi:10.1111/bjh.17140
NLM
Oliveira BQ de, Catto LFB, Santana BAA, Tellechea MF, Scheucher PS, Scheinberg P, Calado RT. Eltrombopag preferentially expands haematopoietic multipotent progenitors in human aplastic anaemia [Internet]. British Journal of Haematology. 2021 ; 193( 2): 410-414.[citado 2025 nov. 24 ] Available from: https://doi.org/10.1111/bjh.17140
Vancouver
Oliveira BQ de, Catto LFB, Santana BAA, Tellechea MF, Scheucher PS, Scheinberg P, Calado RT. Eltrombopag preferentially expands haematopoietic multipotent progenitors in human aplastic anaemia [Internet]. British Journal of Haematology. 2021 ; 193( 2): 410-414.[citado 2025 nov. 24 ] Available from: https://doi.org/10.1111/bjh.17140
Artigo de periodico
NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia (2021)
Ribeiro, Renata Scopim ; Machado Neto, João Agostinho ; Eide, Christopher A. ; Silva, Juan Luiz Coelho da ; Fenerich, Bruna Alves ; Fernandes, Jaqueline Cristina; Scheucher, Priscila Santos ; Stevens, Samantha L. Savage ; Campos, Paula de Melo; Saad, Sara T. Olalla ; Palma, Leonardo de Carvalho ; Pontes, Lorena Lobo de Figueiredo ; Simões, Belinda Pinto ; Rego, Eduardo Magalhães ; Tognon, Cristina E. ; Druker, Brian J. ; Traina, Fabiola
Source: Investigational New Drugs. Unidades: ICB, FMRP, FM
Subjects: FARMACOLOGIA, LEUCEMIA MIELOIDE, INSULINA, ANTINEOPLÁSICOS, PROTEÍNAS QUINASES, CÉLULAS SANGUÍNEAS, PROLIFERAÇÃO CELULAR, APOPTOSE, ONCOGENES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
RIBEIRO, Renata Scopim et al. NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia. Investigational New Drugs, v. 39, n. 3, p. 736-746, 2021Tradução . . Disponível em: https://doi.org/10.1007/s10637-020-01028-8. Acesso em: 24 nov. 2025.
APA
Ribeiro, R. S., Machado Neto, J. A., Eide, C. A., Silva, J. L. C. da, Fenerich, B. A., Fernandes, J. C., et al. (2021). NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia. Investigational New Drugs, 39( 3), 736-746. doi:10.1007/s10637-020-01028-8
NLM
Ribeiro RS, Machado Neto JA, Eide CA, Silva JLC da, Fenerich BA, Fernandes JC, Scheucher PS, Stevens SLS, Campos P de M, Saad STO, Palma L de C, Pontes LL de F, Simões BP, Rego EM, Tognon CE, Druker BJ, Traina F. NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia [Internet]. Investigational New Drugs. 2021 ; 39( 3): 736-746.[citado 2025 nov. 24 ] Available from: https://doi.org/10.1007/s10637-020-01028-8
Vancouver
Ribeiro RS, Machado Neto JA, Eide CA, Silva JLC da, Fenerich BA, Fernandes JC, Scheucher PS, Stevens SLS, Campos P de M, Saad STO, Palma L de C, Pontes LL de F, Simões BP, Rego EM, Tognon CE, Druker BJ, Traina F. NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia [Internet]. Investigational New Drugs. 2021 ; 39( 3): 736-746.[citado 2025 nov. 24 ] Available from: https://doi.org/10.1007/s10637-020-01028-8
Trabalho de evento-resumo periodico
Eltrombopag specifically expands hematopoietic multipotent progenitors in human aplastic anemia (2020)
Oliveira, Bruno Quintino; Santana, Bárbara; Catto, Luiz Fernando Bazzo ; Tellechea, Maria Florencia; Scheucher, Priscila Santos; Scheinberg, Phillip; Calado, Rodrigo Tocantins
Source: Blood. Conference titles: ASH Annual Meeting and Exposition. Unidade: FMRP
Subjects: ANEMIA, HEMATOPOESE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
OLIVEIRA, Bruno Quintino et al. Eltrombopag specifically expands hematopoietic multipotent progenitors in human aplastic anemia. Blood. Washington: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1182/blood-2020-142746. Acesso em: 24 nov. 2025. , 2020
APA
Oliveira, B. Q., Santana, B., Catto, L. F. B., Tellechea, M. F., Scheucher, P. S., Scheinberg, P., & Calado, R. T. (2020). Eltrombopag specifically expands hematopoietic multipotent progenitors in human aplastic anemia. Blood. Washington: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. doi:10.1182/blood-2020-142746
NLM
Oliveira BQ, Santana B, Catto LFB, Tellechea MF, Scheucher PS, Scheinberg P, Calado RT. Eltrombopag specifically expands hematopoietic multipotent progenitors in human aplastic anemia [Internet]. Blood. 2020 ; 136 [3] .[citado 2025 nov. 24 ] Available from: https://doi.org/10.1182/blood-2020-142746
Vancouver
Oliveira BQ, Santana B, Catto LFB, Tellechea MF, Scheucher PS, Scheinberg P, Calado RT. Eltrombopag specifically expands hematopoietic multipotent progenitors in human aplastic anemia [Internet]. Blood. 2020 ; 136 [3] .[citado 2025 nov. 24 ] Available from: https://doi.org/10.1182/blood-2020-142746
Artigo de periodico
Interleukin-8 is not a predictive biomarker for the development of the acute promyelocytic leukemia differentiation syndrome (2020)
Almeida, Luciana Yamamoto de ; Martins, Diego Antonio Pereira ; Lima, Ana Silvia Gouvêa; Baggio, Marcia Sueli; Koury, Luisa Correa de Araujo; Lange, Ana Paula; Bassi, Sarah Cristina; Scheucher, Priscila Santos ; Rego, Eduardo Magalhães
Source: Bmc cancer. Unidades: FMRP, FM
Subjects: LEUCEMIA, INTERLEUCINA 6, INTERLEUCINA 8
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ALMEIDA, Luciana Yamamoto de et al. Interleukin-8 is not a predictive biomarker for the development of the acute promyelocytic leukemia differentiation syndrome. Bmc cancer, v. 20, n. 1, 2020Tradução . . Disponível em: https://doi.org/10.1186/s12885-020-07330-1. Acesso em: 24 nov. 2025.
APA
Almeida, L. Y. de, Martins, D. A. P., Lima, A. S. G., Baggio, M. S., Koury, L. C. de A., Lange, A. P., et al. (2020). Interleukin-8 is not a predictive biomarker for the development of the acute promyelocytic leukemia differentiation syndrome. Bmc cancer, 20( 1). doi:10.1186/s12885-020-07330-1
NLM
Almeida LY de, Martins DAP, Lima ASG, Baggio MS, Koury LC de A, Lange AP, Bassi SC, Scheucher PS, Rego EM. Interleukin-8 is not a predictive biomarker for the development of the acute promyelocytic leukemia differentiation syndrome [Internet]. Bmc cancer. 2020 ; 20( 1):[citado 2025 nov. 24 ] Available from: https://doi.org/10.1186/s12885-020-07330-1
Vancouver
Almeida LY de, Martins DAP, Lima ASG, Baggio MS, Koury LC de A, Lange AP, Bassi SC, Scheucher PS, Rego EM. Interleukin-8 is not a predictive biomarker for the development of the acute promyelocytic leukemia differentiation syndrome [Internet]. Bmc cancer. 2020 ; 20( 1):[citado 2025 nov. 24 ] Available from: https://doi.org/10.1186/s12885-020-07330-1
Artigo de periodico
Autophagy inhibition potentiates ruxolitinib-induced apoptosis in JAK2V617F cells (2020)
Machado Neto, João Agostinho ; Silva, Juan Luiz Coelho da ; Santos, Fábio Pires de Souza ; Scheucher, Priscila Santos ; Campregher, Paulo Vidal ; Hamerschlak, Nelson ; Rego, Eduardo Magalhães ; Traina, Fabiola
Source: Investigational New Drugs. Unidades: ICB, FMRP
Subjects: FARMACOLOGIA, APOPTOSE, LEUCEMIA MIELOIDE AGUDA, NEOPLASIAS POR TIPO HISTOLÓGICO, ANTIMALÁRICOS, CÉLULAS MIELOIDES, CÉLULAS SANGUÍNEAS, ERITRÓCITOS, MUTAÇÃO GENÉTICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MACHADO NETO, João Agostinho et al. Autophagy inhibition potentiates ruxolitinib-induced apoptosis in JAK2V617F cells. Investigational New Drugs, v. 38, p. 733–745, 2020Tradução . . Disponível em: https://doi.org/10.1007/s10637-019-00812-5. Acesso em: 24 nov. 2025.
APA
Machado Neto, J. A., Silva, J. L. C. da, Santos, F. P. de S., Scheucher, P. S., Campregher, P. V., Hamerschlak, N., et al. (2020). Autophagy inhibition potentiates ruxolitinib-induced apoptosis in JAK2V617F cells. Investigational New Drugs, 38, 733–745. doi:10.1007/s10637-019-00812-5
NLM
Machado Neto JA, Silva JLC da, Santos FP de S, Scheucher PS, Campregher PV, Hamerschlak N, Rego EM, Traina F. Autophagy inhibition potentiates ruxolitinib-induced apoptosis in JAK2V617F cells [Internet]. Investigational New Drugs. 2020 ; 38 733–745.[citado 2025 nov. 24 ] Available from: https://doi.org/10.1007/s10637-019-00812-5
Vancouver
Machado Neto JA, Silva JLC da, Santos FP de S, Scheucher PS, Campregher PV, Hamerschlak N, Rego EM, Traina F. Autophagy inhibition potentiates ruxolitinib-induced apoptosis in JAK2V617F cells [Internet]. Investigational New Drugs. 2020 ; 38 733–745.[citado 2025 nov. 24 ] Available from: https://doi.org/10.1007/s10637-019-00812-5
Artigo de periodico
NTAL is associated with treatment outcome, cell proliferation and differentiation in acute promyelocytic leukemia (2020)
Thomé, Carolina Hassibe ; Ferreira, Germano Aguiar ; Martins, Diego Antonio Pereira ; Santos, Guilherme Augusto dos; Ortiz, César Alexander; Souza, Lucas Eduardo Botelho de ; Sobral, Lays Martins; Silva, Cleide Lúcia Araújo; Scheucher, Priscila Santos ; Gil, Cristiane Damas; Leopoldino, Andréia Machado ; Silveira, Douglas Rafaele Almeida ; Silva, Juan Luiz Coelho da ; Traina, Fabiola ; Koury, Luisa C.; Melo, Raul A. M.; Bittencourt, Rosane; Pagnano, Katia; Pasquini, Ricardo; Nunes, Elenaide C.; Fagundes, Evandro M.; Gloria, Ana Beatriz F.; kerbauy, Fábio Rodrigues; Chauffaille, Maria de Lourdes; Keating, Armand; Tallman, Martin S.; Ribeiro, Raul C.; Dillon, Richard; Ganser, Arnold; Löwenberg, Bob; Valk, Peter; Lo-Coco, Francesco; Sanz, Miguel A.; Berliner, Nancy; Faça, Vitor Marcel ; Rego, Eduardo Magalhaes
Source: Scientific Reports. Unidades: FMRP, FCFRP, FM
Subjects: PROTEÍNAS, TRANSDUÇÃO DE SINAL CELULAR, QUIMIOTERAPIA, ANTINEOPLÁSICOS, MEDULA ÓSSEA, DIFERENCIAÇÃO CELULAR, SOBREVIVÊNCIA CELULAR, LEUCEMIA, FARMACOTERAPIA, ANÁLISE DE SOBREVIVÊNCIA, ESTUDOS RETROSPECTIVOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
THOMÉ, Carolina Hassibe et al. NTAL is associated with treatment outcome, cell proliferation and differentiation in acute promyelocytic leukemia. Scientific Reports, v. 10, n. 1, 2020Tradução . . Disponível em: https://doi.org/10.1038/s41598-020-66223-2. Acesso em: 24 nov. 2025.
APA
Thomé, C. H., Ferreira, G. A., Martins, D. A. P., Santos, G. A. dos, Ortiz, C. A., Souza, L. E. B. de, et al. (2020). NTAL is associated with treatment outcome, cell proliferation and differentiation in acute promyelocytic leukemia. Scientific Reports, 10( 1). doi:10.1038/s41598-020-66223-2
NLM
Thomé CH, Ferreira GA, Martins DAP, Santos GA dos, Ortiz CA, Souza LEB de, Sobral LM, Silva CLA, Scheucher PS, Gil CD, Leopoldino AM, Silveira DRA, Silva JLC da, Traina F, Koury LC, Melo RAM, Bittencourt R, Pagnano K, Pasquini R, Nunes EC, Fagundes EM, Gloria ABF, kerbauy FR, Chauffaille M de L, Keating A, Tallman MS, Ribeiro RC, Dillon R, Ganser A, Löwenberg B, Valk P, Lo-Coco F, Sanz MA, Berliner N, Faça VM, Rego EM. NTAL is associated with treatment outcome, cell proliferation and differentiation in acute promyelocytic leukemia [Internet]. Scientific Reports. 2020 ; 10( 1):[citado 2025 nov. 24 ] Available from: https://doi.org/10.1038/s41598-020-66223-2
Vancouver
Thomé CH, Ferreira GA, Martins DAP, Santos GA dos, Ortiz CA, Souza LEB de, Sobral LM, Silva CLA, Scheucher PS, Gil CD, Leopoldino AM, Silveira DRA, Silva JLC da, Traina F, Koury LC, Melo RAM, Bittencourt R, Pagnano K, Pasquini R, Nunes EC, Fagundes EM, Gloria ABF, kerbauy FR, Chauffaille M de L, Keating A, Tallman MS, Ribeiro RC, Dillon R, Ganser A, Löwenberg B, Valk P, Lo-Coco F, Sanz MA, Berliner N, Faça VM, Rego EM. NTAL is associated with treatment outcome, cell proliferation and differentiation in acute promyelocytic leukemia [Internet]. Scientific Reports. 2020 ; 10( 1):[citado 2025 nov. 24 ] Available from: https://doi.org/10.1038/s41598-020-66223-2
Trabalho de evento-resumo periodico
High frequency of leukemic stem cells is associated with adverse prognosis in a Brazilian cohort of acute myeloid leukemia with normal karyotype (2020)
Jacovelli, Gustavo Leite; Costa, A. F. O.; Marani, Leticia Olops; Madeira, M. I. A.; Scheucher, Priscila Santos; Silva, F. B.; Lima, Ana Silvia Gouvêa de; Duarte, B .K.; Pagnano, K. B.; Kerbauy, Fábio Rodrigues; Feliciano, J. V.P.; Higashi, M.; Nunes, E. C.; Fagundes, E. M.; Gloria, A. B. F.; Rego, Eduardo Magalhães; Traina, Fabiola; Pontes, Lorena Lobo de Figueiredo
Source: Hematology, Transfusion and Cell Therapy. Conference titles: Congresso Brasileiro de Hematologia, Hemoterapia e Terapia Celular - HemoPlay. Unidades: FMRP, FM
Subjects: HEMATOLOGIA, LEUCEMIA, MEDULA ÓSSEA, CÉLULAS-TRONCO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
JACOVELLI, Gustavo Leite et al. High frequency of leukemic stem cells is associated with adverse prognosis in a Brazilian cohort of acute myeloid leukemia with normal karyotype. Hematology, Transfusion and Cell Therapy. São José do Rio Preto: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1016/j.htct.2020.10.259. Acesso em: 24 nov. 2025. , 2020
APA
Jacovelli, G. L., Costa, A. F. O., Marani, L. O., Madeira, M. I. A., Scheucher, P. S., Silva, F. B., et al. (2020). High frequency of leukemic stem cells is associated with adverse prognosis in a Brazilian cohort of acute myeloid leukemia with normal karyotype. Hematology, Transfusion and Cell Therapy. São José do Rio Preto: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. doi:10.1016/j.htct.2020.10.259
NLM
Jacovelli GL, Costa AFO, Marani LO, Madeira MIA, Scheucher PS, Silva FB, Lima ASG de, Duarte B .K, Pagnano KB, Kerbauy FR, Feliciano JVP, Higashi M, Nunes EC, Fagundes EM, Gloria ABF, Rego EM, Traina F, Pontes LL de F. High frequency of leukemic stem cells is associated with adverse prognosis in a Brazilian cohort of acute myeloid leukemia with normal karyotype [Internet]. Hematology, Transfusion and Cell Therapy. 2020 ; 42 S153-S154.[citado 2025 nov. 24 ] Available from: https://doi.org/10.1016/j.htct.2020.10.259
Vancouver
Jacovelli GL, Costa AFO, Marani LO, Madeira MIA, Scheucher PS, Silva FB, Lima ASG de, Duarte B .K, Pagnano KB, Kerbauy FR, Feliciano JVP, Higashi M, Nunes EC, Fagundes EM, Gloria ABF, Rego EM, Traina F, Pontes LL de F. High frequency of leukemic stem cells is associated with adverse prognosis in a Brazilian cohort of acute myeloid leukemia with normal karyotype [Internet]. Hematology, Transfusion and Cell Therapy. 2020 ; 42 S153-S154.[citado 2025 nov. 24 ] Available from: https://doi.org/10.1016/j.htct.2020.10.259
Artigo de periodico
NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2V617F-positive myeloproliferative neoplasm cells (2020)
Fenerich, Bruna Alves ; Fernandes, Jaqueline Cristina; Alves, Ana Paula Nunes Rodrigues; Silva, Juan Luiz Coelho da ; Ribeiro, Renata Scopim; Scheucher, Priscila Santos ; Eide, Christopher A.; Tognon, Cristina E.; Druker, Brian J. ; Rego, Eduardo Magalhães ; Machado Neto, João Agostinho ; Traina, Fabiola
Source: Signal Transduction and Targeted Therapy. Unidades: FMRP, FM, ICB
Subjects: FARMACOLOGIA, TRANSDUÇÃO DE SINAL CELULAR, CÉLULAS CULTIVADAS DE TUMOR, ANTINEOPLÁSICOS, PROLIFERAÇÃO CELULAR, ERITROPOIETINA, APOPTOSE, MUTAÇÃO GENÉTICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FENERICH, Bruna Alves et al. NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2V617F-positive myeloproliferative neoplasm cells. Signal Transduction and Targeted Therapy, p. 10 , 2020Tradução . . Disponível em: https://doi.org/10.1038/s41392-019-0102-5. Acesso em: 24 nov. 2025.
APA
Fenerich, B. A., Fernandes, J. C., Alves, A. P. N. R., Silva, J. L. C. da, Ribeiro, R. S., Scheucher, P. S., et al. (2020). NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2V617F-positive myeloproliferative neoplasm cells. Signal Transduction and Targeted Therapy, 10 . doi:10.1038/s41392-019-0102-5
NLM
Fenerich BA, Fernandes JC, Alves APNR, Silva JLC da, Ribeiro RS, Scheucher PS, Eide CA, Tognon CE, Druker BJ, Rego EM, Machado Neto JA, Traina F. NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2V617F-positive myeloproliferative neoplasm cells [Internet]. Signal Transduction and Targeted Therapy. 2020 ; 10 .[citado 2025 nov. 24 ] Available from: https://doi.org/10.1038/s41392-019-0102-5
Vancouver
Fenerich BA, Fernandes JC, Alves APNR, Silva JLC da, Ribeiro RS, Scheucher PS, Eide CA, Tognon CE, Druker BJ, Rego EM, Machado Neto JA, Traina F. NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2V617F-positive myeloproliferative neoplasm cells [Internet]. Signal Transduction and Targeted Therapy. 2020 ; 10 .[citado 2025 nov. 24 ] Available from: https://doi.org/10.1038/s41392-019-0102-5
Trabalho de evento-resumo periodico
Association of natural killer cells functional subtypes with genetic risk stratification in acute myeloid leukemia (2020)
Costa, A. F. O.; Marani, Leticia Olops; Jacovelli, Gustavo Leite; Coelho, J. L.; Bianco, Thiago Mantello; Lopes, Izabela Aparecida; Scheucher, Priscila Santos; Schiavinato, Josiane Lilian dos Santos ; Pagnano, K.; Duarte, B. K.; Kerbauy, Fábio Rodrigues; Higashi, M.; Nunes, E.; Fagundes, E.; Gloria, A. B. F.; Rego, Eduardo Magalhães; Traina, Fabiola; Pontes, Lorena Lobo de Figueiredo
Source: Hematology, Transfusion and Cell Therapy. Conference titles: Congresso Brasileiro de Hematologia, Hemoterapia e Terapia Celular - HemoPlay. Unidades: FMRP, FM
Subjects: LEUCEMIA MIELOIDE AGUDA, SISTEMA IMUNE, MEDULA ÓSSEA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
COSTA, A. F. O. et al. Association of natural killer cells functional subtypes with genetic risk stratification in acute myeloid leukemia. Hematology, Transfusion and Cell Therapy. São José do Rio Preto: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1016/j.htct.2020.10.243. Acesso em: 24 nov. 2025. , 2020
APA
Costa, A. F. O., Marani, L. O., Jacovelli, G. L., Coelho, J. L., Bianco, T. M., Lopes, I. A., et al. (2020). Association of natural killer cells functional subtypes with genetic risk stratification in acute myeloid leukemia. Hematology, Transfusion and Cell Therapy. São José do Rio Preto: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. doi:10.1016/j.htct.2020.10.243
NLM
Costa AFO, Marani LO, Jacovelli GL, Coelho JL, Bianco TM, Lopes IA, Scheucher PS, Schiavinato JL dos S, Pagnano K, Duarte BK, Kerbauy FR, Higashi M, Nunes E, Fagundes E, Gloria ABF, Rego EM, Traina F, Pontes LL de F. Association of natural killer cells functional subtypes with genetic risk stratification in acute myeloid leukemia [Internet]. Hematology, Transfusion and Cell Therapy. 2020 ; 42 S143-S144.[citado 2025 nov. 24 ] Available from: https://doi.org/10.1016/j.htct.2020.10.243
Vancouver
Costa AFO, Marani LO, Jacovelli GL, Coelho JL, Bianco TM, Lopes IA, Scheucher PS, Schiavinato JL dos S, Pagnano K, Duarte BK, Kerbauy FR, Higashi M, Nunes E, Fagundes E, Gloria ABF, Rego EM, Traina F, Pontes LL de F. Association of natural killer cells functional subtypes with genetic risk stratification in acute myeloid leukemia [Internet]. Hematology, Transfusion and Cell Therapy. 2020 ; 42 S143-S144.[citado 2025 nov. 24 ] Available from: https://doi.org/10.1016/j.htct.2020.10.243
Artigo de periodico
IGF1R/IRS1 targeting has cytotoxic activity and inhibits PI3K/AKT/mTOR and MAPK signaling in acute lymphoblastic leukemia cells (2019)
Alves, Ana Paula Nunes Rodrigues; Fernandes, Jaqueline Cristina; Fenerich, Bruna Alves ; Silva, Juan Luiz Coelho da; Scheucher, Priscila Santos ; Simões, Belinda Pinto ; Rego, Eduardo Magalhaes ; Ridley, Anne J. ; Machado Neto, João Agostinho ; Traina, Fabiola
Source: Cancer Letters. Unidades: FMRP, FM, ICB
Subjects: LEUCEMIA, CÉLULAS SANGUINEAS, CITOTOXINAS, APOPTOSE, CÉLULAS CULTIVADAS DE TUMOR, ONCOGENES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ALVES, Ana Paula Nunes Rodrigues et al. IGF1R/IRS1 targeting has cytotoxic activity and inhibits PI3K/AKT/mTOR and MAPK signaling in acute lymphoblastic leukemia cells. Cancer Letters, v. 456, p. 59-68, 2019Tradução . . Disponível em: https://doi.org/10.1016/j.canlet.2019.04.030. Acesso em: 24 nov. 2025.
APA
Alves, A. P. N. R., Fernandes, J. C., Fenerich, B. A., Silva, J. L. C. da, Scheucher, P. S., Simões, B. P., et al. (2019). IGF1R/IRS1 targeting has cytotoxic activity and inhibits PI3K/AKT/mTOR and MAPK signaling in acute lymphoblastic leukemia cells. Cancer Letters, 456, 59-68. doi:10.1016/j.canlet.2019.04.030
NLM
Alves APNR, Fernandes JC, Fenerich BA, Silva JLC da, Scheucher PS, Simões BP, Rego EM, Ridley AJ, Machado Neto JA, Traina F. IGF1R/IRS1 targeting has cytotoxic activity and inhibits PI3K/AKT/mTOR and MAPK signaling in acute lymphoblastic leukemia cells [Internet]. Cancer Letters. 2019 ; 456 59-68.[citado 2025 nov. 24 ] Available from: https://doi.org/10.1016/j.canlet.2019.04.030
Vancouver
Alves APNR, Fernandes JC, Fenerich BA, Silva JLC da, Scheucher PS, Simões BP, Rego EM, Ridley AJ, Machado Neto JA, Traina F. IGF1R/IRS1 targeting has cytotoxic activity and inhibits PI3K/AKT/mTOR and MAPK signaling in acute lymphoblastic leukemia cells [Internet]. Cancer Letters. 2019 ; 456 59-68.[citado 2025 nov. 24 ] Available from: https://doi.org/10.1016/j.canlet.2019.04.030

USP Schools

ReP

Filtros

Departament

Authors

USP affiliated authors

Date published

Subjects

Source title

Conference titles

Countries/Territories

Funding Agencies

Indexado em

Non normalized affiliation

Countries of institutions of collaboration